MARIA CLAUDIA NOGUEIRA ZERBINI
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Patologia, Faculdade de Medicina - Docente
LIM/14 - Laboratório de Investigação em Patologia Hepática, Hospital das Clínicas, Faculdade de Medicina
LIM/14 - Laboratório de Investigação em Patologia Hepática, Hospital das Clínicas, Faculdade de Medicina
2 resultados
Resultados de Busca
Agora exibindo 1 - 2 de 2
article 10 Citação(ões) na Scopus World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008-major changes from the 3rd edition, 2001(2011) ZERBINI, Maria Claudia Nogueira; SOARES, Fernando Augusto; VELLOSO, Elvira Deolinda Rodrigues Pereira; CHAUFAILLE, Maria de Lourdes L. F.; PAES, Roberto PintoWorld Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 - major changes from the 3rd edition, 2001 The World Health Organization (WHO) Classification of tumors of hematopoietic and lymphoid tissues (4th edition, 2008)(1) presents an updated version of the 3rd edition published in 2001(2). A summary of these changes relates to the groups of chronic myeloproliferative disorders, myelodisplasia, acute myeloid leukemias, neoplasms of precursor B and T cells and neoplasms derived of mature B, T and NK cells. A better understanding of molecular genetic changes and results achieved with innovative therapeutic approaches in these groups of diseases requires constant reassessment of the classifications, supporting the major changes discussed here, including interesting comments from literature(1,3-5).- P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms' Tumor(2011) TEIXEIRA, Roberto Augusto Plaza; ODONE-FILHO, Vicente; CAMARGO, Beatriz de; ZERBINI, Maria Claudia; FILLIPI, Renne; ALENCAR, Arlaine; CRISTOFANI, LilianFifteen percent of patients with Wilms'' tumor (WT) experience relapse. It has been suggested that weight and age may affect the chances of relapse. Few studies have investigated the role, if any, between P-glycoprotein (P-gp) and relapse. The authors assessed the prognostic value of tumor weight and age at diagnosis and asked whether some other potential biological markers, specifically P-gp protein expression, had a prognostic value in favorable-histology WT. No association between age and relapse could be found. Patients with tumor weight >= a parts per thousand yen550 g were 6 times more likely to relapse, whereas P-gp expression was positive in 18/40 (45%%) of the patients, of which 10/12 (83.3%%) relapsed and 8/28 (28.6%%) did not. Further studies are necessary to elucidate whether or not P-gp is related to relapse in patients with histologically favorable Wilms'' tumor. If confirmed, the protein may be used in the future as a target for new drugs and treatments for this group of patients.